

# PROGRAM



## **LATAM-UZA NET** PRECEPTORSHIP

## WELCOME TO THE FIRST EDITION OF THE



### NETwerk MISSION AND BACKGROUND

**NETwerk** is a hospital-network consisting of eight Belgian hospitals, including the University Hospital of Antwerp, which was developed aiming to improve the diagnosis and treatment of patients with **Neuroendocrine Tumors (NET)** in a multidisciplinary, multicenter, and scientific framework. The goal is to join forces within the **NETwerk** to provide an excellent care to the patients based on the comprehensive knowledge and expertise on NET of all the members who are part of the **NETwerk**. A key feature of this approach is the joined NET multidisciplinary board on a biweekly basis to discuss the best diagnosis and treatment approach of NET patients.

The **European Neuroendocrine Tumor Society (ENETS)** developed a list of criteria a center should meet to attain the ENETS **Center of Excellence** certificate. Only hospitals meeting all these criteria and having demonstrated excellence in neuroendocrine tumor patients care during an audit can claim this certification. Thus, in 2017, the **NETwerk** successfully met these criteria and became the **first ENETS Network of Excellence** in Europe.

**The mission statement of the NETwerk focuses on three main pillars:**

- 1) **Multidisciplinary and multicenter medical approach:** **NETwerk** consists of all caregivers involved in neuroendocrine neoplasms, from the medical specialists to the nurses
- 2) Quality through outstanding clinical and preclinical research
- 3) **Patient-centered decisions:** always close to the patient. All physicians from all the **NETwerk** hospitals are committed to work together with one goal in mind: **excellence in NET patient care.**

## MARC PEETERS, MD (BELGIUM)



**Prof. Dr. Marc Peeters, is head of the Oncology department at the Antwerp University Hospital and coordinator of the Oncology Health Program.** He is currently chairman of both the Belgian College of Oncology and Belgian Group of Digestive Oncology and works as Professor of Oncology at the Antwerp University, the Ghent University (both in Belgium) and University of Adelaide (Australia). Over the last ten years, Prof. Marc Peeters was the central principal investigator of approximately 34 academic trials, of which several were multicenter and randomized clinical trials. He has built up extensive experience in the design, conduct and successful completion of investigator-initiated trials in oncology. His research interests include the identification of molecular markers and therapy modulation in digestive tumours. He published more than 400 articles in peer reviewed journals and was author of several chapters in oncology books.

**Dr. Peeters has been an active member of the European Neuroendocrine Tumour Society (ENETS) since 2015,** and he is current member of its Advisory Board. In addition, he is the head of the NETwerk since 2016. Dr. Peeters has a lot of experience as (principal) investigator of several NET related clinical trials.

## TIMON VANDAMME, PhD, MD (BELGIUM)



**Timon Vandamme is a certified clinical oncologist. He is consultant in digestive and neuroendocrine oncology at the University Hospital Antwerp.** He pursued a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, Rotterdam, the Netherlands on everolimus resistance and pancreatic neuroendocrine tumor genomics. His research has led to multiple publications in peer-reviewed journals and was funded by The Research Foundation - Flanders (FWO) and Stichting tegen Kanker. During his PhD, he was involved in the development of the NETwerk, the first European Neuroendocrine Tumor Society (ENETS) Network of Excellence based in Antwerp, Belgium. Currently, he serves as a NETwerk Coordinator and member of the Steering Committee. He has presented his research at various national and international conferences, including three oral presentations at ENETS. His research won different awards, including the ENETS-Ipsen Translational Research Fellowship in 2013. He serves as editorial reviewer for various international journals.

### **ROCÍO DEL PILAR LÓPEZ PANQUEVA, MD (COLOMBIA)**



**Dr. Rocío López is a certified pathologist currently working at the Universidad Nacional de Colombia and she is an institutional pathologist at the University Hospital of Fundación Santa Fe de Bogotá (FSFB).** Dr. López completed her fellowship in pathology at the Fundación Santa Fe de Bogotá. Her practice and clinical research are focused on Gastrointestinal, Pancreatic and Liver pathology. She is also an Associate professor of Medicine School at Universidad de Los Andes. Dr. López is an active member of the Colciencias research group working on complex diseases of the FSFB/UniAndes, projects particularly related to gastrointestinal and liver tumors and non-tumor pathology, transplantation pathology, and neuroendocrine tumors.

### **JULIETA GRASELLI, PhD, MD (ARGENTINA)**



**Dr. Julieta Grasselli is a certified clinical oncologist. She is currently the Head of the Gastroenterology Tumors Unit at the CEMIC University Hospital in Buenos Aires.** Dr. Grasselli attained a PhD degree in medical science in 2018 by the University of Barcelona in Spain. Dr. Grasselli has also an Immune-Oncology certification by the University of Navarra, Spain. She has been the principal investigator for multiple phase I/II/III trials sponsored by the pharmaceutical industry. Dr. Grasselli is also an active investigator in translational oncology research with several of this works published between 2016 and 2019.

### **MARCELO GARRIDO, MD (CHILE)**



**Dr. Marcelo Garrido Salvo is a certified clinical oncologist with his clinical practice focused on digestive tumors as an Associate Professor of the Gastrointestinal Medical Oncology Department at the Pontificia Universidad Católica.** He finalized his training on digestive oncology in 2013 at the Asturias University in Spain. Dr. Garrido has conducted several clinical trials in oncology at the Cancer Center of the Clínica San Carlos de Apoquindo, at the Health Network UC-Christus, and at the Pontificia Universidad Católica de Chile. Dr. Garrido has been the principal investigator for multiple phase II/III trials sponsored by the pharmaceutical industry. He has published more than 50 works as a result of his oncology clinical research since 1998 up to 2019.

## IVÁN BUSTILLO, MD (COLOMBIA)



**Dr. Iván Bustillo is a certified clinical oncologist. He is currently the Head of the Oncology Department at Clínica Portoazul.** Dr. Bustillo performed a fellowship in internal medicine at the Yale University Medical School and a fellowship in clinical oncology at the Roswell Park Cancer Institute in the United States. He also attained an international diploma on Molecular Biology applied to clinical oncology by the Canadian Health Council and by University of Liege in Belgium. He is currently professor of internal medicine subject of the Clinical Oncology cathedra and Director of the Clinical Oncology sub-specialty at the Universidad del Norte.

## ANN DRIESSEN, MD (BELGIUM)



## HANS HOFLAND, PhD, MD (NETHERLANDS)

**Dr. Hans Hofland is a consultant endocrinologist at the Erasmus Medical Centre in Rotterdam, the Netherlands.** He completed his PhD with honours on the production and effects of steroid hormones in endocrine tumors at the same institute. This was followed by an ERC Marie-Curie Intra-European fellowship at the University of Birmingham, United Kingdom. He currently participates in specialised endocrine oncology clinics and is the medical lead for peptide receptor radionuclide therapy within the Erasmus MC, an ENETS Center of Excellence. His key research interests are translational approaches to discover novel biomarkers and improve therapeutic options for neuroendocrine tumor patients, with a particular focus on radionuclide therapy.

## SIGRID STROOBANTS, PhD, MD (BELGIUM)



**Dr. Sigrid Stroobants received her medical degree and postgraduate training in nuclear medicine at the Catholic University in Leuven, Belgium.** She became a staff member in the department of Nuclear Medicine at the University Hospital Gasthuisberg, Leuven from 1998 onwards. She obtained her PhD in 2002 on the use of PET scan for diagnosis and treatment response assessment in lung cancer patients. In 2008, she moved to the University of Antwerp (UA) to become the head of the department of Nuclear Medicine at the University Hospital (UZA). In 2010, she also became director of the Molecular Imaging Center Antwerp (MICA), which combines a preclinical nuclear imaging facility (UA) and a cyclotron with GMP radiopharmacy (UZA) enabling also more fundamental and translational research. Researchers were recruited all over the globe and the team exponentially grew to a total of more than 30 co-workers. The research focus of the team is on the development and validation of new imaging biomarkers in neurology and oncology to support personalized medicine. Dr. Stroobants is (co-)author of more than 184 scientific papers (29/01/2021 h-index=49, > 15941 citation).

## MARC SIMOENS, MD (BELGIUM)



**Dr. Marc Simoens is a certified gastroenterologist and clinical oncologist specialized on digestive tumors.** He is the current Head of the Gastroenterology Department at the Hospital Network Antwerp (ZNA). Dr. Simoens is an active member of the NETwerk multidisciplinary team. He has presented several posters on clinical research in the annual or conference meetings of ESMO and ENETS, among others.

## WILLEM LYBAERT, MD (BELGIUM)



**Dr. Willem Lybaert is a certified clinical oncologist with clinical practice started 15 years ago at the University Hospital AZ Nikolaas, University Hospital AZ Lokeren, and currently at the UZA (Antwerp University Hospital).** He is mainly focused on digestive oncology, head and neck cancers, and neuroendocrine tumours within ENETS CoE Antwerp-Waasland. Dr. Lybaert is member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) and a board member of the British Society of Medical Oncology (BSMO).

### LAURE-ANNE TEUWEN, MD (BELGIUM)



**Dr. Laure-Anne Teuwen received her medical degree at the Catholic University of Leuven, Belgium** and is currently a fellow medical oncology at the Antwerp University Hospital as well as a PhD fellow at the Antwerp University and Catholic University of Leuven. Her research topic concerns tumor vessel co-option, where she uses single-cell RNA sequencing and imaging techniques to decipher the contribution of different cellular players. After obtaining her PhD, she would like to engage in global oncology research and education.

### GITTA BOONS, PhD (BELGIUM)



**Prof. Gitta Boons is a certified biochemist and biotechnologist.** She is now a PhD student in medical sciences at the Antwerp University focusing her research on oncology and medical genetics. She has a master degree on molecular biology and cellular gene biotechnology. Prof. Boons has just attained a Bachelor degree on bioinformatics at the Hogeschool West-Vlaanderen (Howest). She was awarded as author of the best poster on basic research at the ENETS annual conference on Diagnosis and Treatment of Neuroendocrine Tumor Disease 2021. Prof. Boons has been the first author in at least three journal articles on basic research (epigenetics and genetics) in NET and she has co-authoring various other cancer basic science papers.

### ANDREAS DOMEN, MD (BELGIUM)



**Dr. Andreas Domen is a medical oncology trainee at the Oncology department of the Antwerp University Hospital,** and he is currently pursuing his PhD on oncogene and therapy-induced cellular senescence in non-small cell lung cancer (NSCLC) at the Center for Oncological Research (CORE) of the University of Antwerp. His research interests include translational approaches to investigate therapy resistance in order to develop novel treatment strategies and enhance prognosis for NSCLC and by extension cancer patients in general.

### HELEEN EGGERS, NURSE (BELGIUM)



**Heleen Eggers is a certified nurse specialized in cancer patient care at the Antwerp University Hospital.** Her clinical practice is focused on symptoms management, supportive care and patients education about their diagnosis and treatment. Oncology nurses also provide emotional support to the patient and their family and have close collaboration with social workers, dieticians, nutritionists, psychologists, pharmacists, and beauticians in order to provide high quality care to cancer patients.

### DIRK VAN GENECHTEN, PATIENT (BELGIUM)



Mr. Dirk Van Genechten is the current Vicepresident of the Neuroendocrine Tumors and Multiple Endocrine Neoplasia patient association, **Vzw NET & MEN Kander Belgische patiëntenvereniging**. Mr. Van Genechten is also a NET patient, and as a survivor of this cancer, he and the NET & MEN cancer patients association provide support to many other patients suffering of NET & MEN.

He is also a current member of the **International Neuroendocrine Cancer Alliance (INCA)** board member, member of the INCA Access Committee, and member of the INCA Membership Committee.

## PROGRAM

### DAY 1 – TUESDAY APRIL 27, 2021

TIME	SESSION TYPE	SPECIALTY	TOPIC	PROFESSOR/ SPEAKER	OBJECTIVE
15 min (19:30–19:45 h, CET)	Plenary	All	Welcome & general information on the virtual preceptorship	<b>Dr. Marc Peeters &amp; Dr. Marcelo Garrido</b>	Welcome & Introduction to UZA and NET research in UZA – introduction of the NET team at UZA – introduction of the 3 LATAM Coordinators. Presentation of the 4-days virtual preceptorship program. General information on how and when to participate, and recommendations for switching between the plenary and the breakout sessions.
50 min (19:45–20:35 h, CET)	Plenary	All	How important is the multidisciplinary approach of NET patients? The NET multidisciplinary team (MDT) at the UZA as an ENETS excellence center	<b>Dr. T. Vandamme</b>	Short video to be presented to show how the MDT works in the UZA hospital. To present ENETS guidelines and recommendations for NET multidisciplinary management: physicians skills, certifications, credentials; health resources & technology minimal requirements; other relevant information. How is the GEP-NET patient managed at the UZA? UZA specific protocol or guidelines to manage NET patients. Importance and structure of a NET tumor board.
15 min (20:35–20:50 h, CET)	<b>COFFEE-BREAK</b>				
35 min (20:50–21:25 h, CET)	Plenary	All	Overview of the multidisciplinary approach of the NET patient in Latin America	<b>Dr. Marcelo Garrido (Chile), Dr. Julieta Grasselli (Argentina), and Dr. Ivan Bustillo (Colombia)</b>	Overview of the availability of resources to manage NET patients in LATAM (targeted therapies, nuclear medicine, etc.). How does the NET multidisciplinary team works in LATAM countries?
20 min (21:25–21:45 h, CET)	Plenary	All	Questions & answers – Closure day 1	<b>All Speakers</b>	

## PROGRAM

### DAY 2 - WEDNESDAY APRIL 28, 2021

TIME	SESSION TYPE	SPECIALTY	TOPIC	PROFESSOR/SPEAKER	OBJECTIVE
70 min (19:30-20:40 h, CET)	<b>Plenary</b>	All	Pancreatic NET-Clinical Cases Discussion	<b>Dr. Laure-Anne Teuwen (UZA) &amp; Dr. Ivan Bustillo (Colombia)</b>	Representative & challenging cases to be presented and discussed. Focused on <b>PANCREATIC NET</b> (three cases to be discussed)
15 min (20:40-20:55 h, CET)	<b>COFFEE-BREAK</b>				
35 min & 15 min for Q&A (20:55-21:45 h, CET)	<b>Breakout session</b>	Oncology/ Endocrinology/ Gastro- enterology	The NET patient journey & Tips and tricks in NET diagnosis	<b>Dr. Marc Simoens</b>	To discuss how is the whole patient journey since the very first symptoms and clinical manifestations of a NET (focused on GEP-NET), medical specialist consulted during the journey (general practitioners, gastroenterologists, internists, etc.). Differential diagnosis, need of awareness of NET among the different medical specialties. Advices to shorten the time to diagnosis.
35 min & 15 min for Q&A (20:55-21:45 h, CET)	<b>Breakout session</b>	Pathology	New WHO 2019 GEP-NET classification: Speaking the same language	<b>Prof. Ann Driessen</b>	To review the evolution of the WHO classification for GI and pancreatic NET. To discuss challenges in G3 NEN differentiation. To discuss the current guidelines and recommendations from the ENETS pathology expert group & the ESP board on the classification of GEP-NET and it's implications for real-life pathology practice.
35 min & 15 min for Q&A (20:55-21:45 h, CET)	<b>Breakout session</b>	Nuclear medicine	Current and new radionuclides to improve NET diagnosis	<b>Dr. Sigrid Stroobants</b>	To discuss current guidelines from the SNMMI (Society of Nuclear Medicine and Molecular Imaging) and the EANM (European Association of Nuclear Medicine). Practical information and tips to be provided.

## PROGRAM

### DAY 3 – THURSDAY APRIL 29, 2021

TIME	SESSION TYPE	SPECIALTY	TOPIC	PROFESSOR/ SPEAKER	OBJECTIVE
70 min (19:30–20:40 h, CET)	<b>Plenary</b>	All	Intestinal-NET Clinical Cases Discussion	<b>Dr. Andreas Domen (UZA) &amp; Dr. Julieta Grasselli (Argentina)</b>	Representative & challenging cases to be presented and discussed. Focused on <b>SMALL INTESTINE NET</b> (three cases to be discussed)
15 min (20:40–20:55 h, CET)	<b>COFFEE-BREAK</b>				
35 min & 15 min for Q&A (20:55–21:45 h, CET)	<b>Breakout session</b>	Oncology/ Endocrinology/ Gastro- enterology	Biomarkers in GEP-NET & lung NET + Basic science overview	<b>Dr. Timon Vandamme &amp; Dr. Gitta Boons</b>	Evidence from basic and clinical research to be discussed. Current biomarkers available and their usefulness in prognosis (evolution) and prediction of therapy response. Useful, practical information to be provided.
35 min & 15 min for Q&A (20:55–21:45 h, CET)	<b>Breakout session</b>	Pathology	Immunohistochemistry for GEP-NET	<b>Prof. Ann Driessen</b>	To review and discuss about immunohistochemistry – practical information to be provided on methodology and techniques.
35 min & 15 min for Q&A (20:55–21:45 h, CET)	<b>Breakout session</b>	Nuclear medicine	Successful PRRT Schemes in GEP-NET & Lung GEP-NET	<b>Dr. Hans Hofland Erasmus</b>	To discuss current guidelines from the SNMMI (Society of Nuclear Medicine and Molecular Imaging) and the EANM (European Association of Nuclear Medicine). To discuss dosing, timing, and sequencing between PRRT and somatostatin analogs. Practical information and tips to be provided. How is response to PRRT assessed?

## PROGRAM

### DAY 4 – FRIDAY APRIL 30, 2021

TIME	SESSION TYPE	SPECIALTY	TOPIC	PROFESSOR/ SPEAKER	OBJECTIVE
35 min (20 min and 15 min for Q&A) (19:30–20:05 h, CET)	Plenary	All	Living with NET: A Patients' Perspective	<b>Mr. Dirk Van Genechten (Patient)</b>	Real-life information of a patient journey, patient's unmet needs in NET diagnosis and treatment. Feedback on doctor-patient relationship: what's good, what's missing.
35 min (20 min and 15 min for Q&A) (20:05–20:40 h, CET)	Plenary	All	Injection experience with somatostatin analogs (SSA) – The nurse perspective	<b>Nurse Heleen Eggers</b>	Real-life information of a nurse experienced in NET therapies. Feedback on her injection experience with somatostatin analogs (SSA) in the real-life setting and in the PRESTO study
15 min (20:40–20:55 h, CET)	<b>COFFEE-BREAK</b>				
35 min & 15 min for Q&A (20:55–21:45 h, CET)	Breakout session	Oncology/ Endocrinology/ Gastro-enterology	Sequencing among the somatostatin analogs in GEP-NET tumor progression: Why, when and how	<b>Dr. Marc Peeters</b>	To present results from clinical trials (mainly from real world evidence) and the UZA own experience. To provide useful information and advice of what patients may benefit of sequencing therapy between octreotide and lanreotide and how to do it.
35 min & 15 min for Q&A (20:55–21:45 h, CET)	Breakout session	Pathology	NET Pathology: The Oncologist – Pathologist interaction	<b>Dr. Willem Lybaert &amp; Dr. Rocío López (Colombia)</b>	Importance of the pathology report for the oncologist in NET management. To discuss what is the oncologist expecting from the pathology report, what are the key data that must be included in the final report. How to improve the interaction between the pathologist and the oncologist for the patient benefit.
35 min & 15 min for Q&A (20:55–21:45 h, CET)	Breakout session	Nuclear medicine	Mechanisms of resistance to PRRT and late complications of PRRT	<b>Dr. Timon Vandamme</b>	To present current knowledge on mechanisms leading to PRRT resistance and how to overcome it
10 min (21:45–21:55 h, CET)	Plenary	All	Take home messages & Closure	<b>Dr. Marc Peeters &amp; Dr. Marcelo Garrido</b>	

